Efficacy, Short Term Safety and Serum Bio Markers In a Clinical Trial of IND#70190
The study shows the efficacy of IND#70190, as well as warrants identification and characterizations of biomarkers for asthma, which is essential for early diagnosis and more effective treatment. Asthma affects 300 million people worldwide as of 2009. The use of IND#70190 would likely have a significant impact on those dealing with asthma.
Dr. Sung Baek and fellow researchers from The Institute of Drug Development had analyzed a natural product blend, known as IND#70190 during the study, on asthma sufferers. In studying the short-term safety and efficacy of the natural product, it was found to have no adverse effects. It was also found that significant inhibition of Matrix Metalloproteinase-9 (MMP-9) correlated with increased airflow. STUDY DETAILS
Researchers: Dr. Sung Baek, Dr. David Campos, Dr. Armando Diaz, Dr. John Cornell, and Dr. Elzbieta Izbicka